title: Optical transfer diagnosis of pigmented lesions: a pilot study.
abstract: OBJECTIVE
  To evaluate the potential of a novel imaging technology, optical transfer diagnosis (OTD), for differentiation of benign from malignant pigmented melanocytic lesions.
  
  
  METHODS
  Patients with pigmented lesions suspicious for melanoma were referred for OTD. After scanning, lesions were biopsied for histopathologic examination, each by two separate dermatopathologists. To create morphologic-physiologic maps, the imaging system used the morphologic and physiologic parameters derived from prediction models of light absorption and scattering by chromophores such as hemoglobin, keratin, and melanin at different epidermal and dermal depths. The relative entropies were analyzed for output prediction of malignancy vs. nonmalignancy.
  
  
  METHODS
  General dermatology clinic in a tertiary care academic medical center.
  
  
  METHODS
  Fifty patients with suspected melanoma.
  
  
  METHODS
  OTD of pigmented lesions suspicious for melanoma, followed by biopsies for histopathologic examination.
  
  
  METHODS
  Histopathologic confirmation of malignant lesions identified by OTD as melanoma.
  
  
  RESULTS
  Sixty-three pigmented suspicious lesions were scanned before being biopsied for histopathologic examination by the two dermatopathologists. Of the 63 lesions, five were identified as melanoma and 58 were found to be benign (including three seborrheic keratoses and 55 melanocytic nevi). OTD was able to identify the malignant lesions with 100% sensitivity and 94.8-96.6% specificity.
  
  
  CONCLUSIONS
  Further study is indicated, but this technology is a promising adjunct to clinical skin cancer screening. Additionally, if the physiologic prediction models can be validated, OTD may facilitate the noninvasive study of some aspects of cutaneous physiology.
authors.affiliation: Department of Dermatology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. swanson.david@mayo.edu
authors.forename: David L
authors.initials: DL
authors.lastname: Swanson
authors.forename: Susan D
authors.initials: SD
authors.lastname: Laman
authors.forename: Marina
authors.initials: M
authors.lastname: Biryulina
authors.forename: Kristian P
authors.initials: KP
authors.lastname: Nielsen
authors.forename: Gennady
authors.initials: G
authors.lastname: Ryzhikov
authors.forename: Jakob J
authors.initials: JJ
authors.lastname: Stamnes
authors.forename: Borge
authors.initials: B
authors.lastname: Hamre
authors.forename: Lu
authors.initials: L
authors.lastname: Zhao
authors.forename: Frank S
authors.initials: FS
authors.lastname: Castellana
authors.forename: Knut
authors.initials: K
authors.lastname: Stamnes
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000175:diagnosis* / Q000378:metabolism; D010859:Pigmentation Disorders / Q000175:diagnosis* / Q000378:metabolism; D010865:Pilot Projects; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D013057:Spectrum Analysis / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor